Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.

Asian Pacific journal of cancer prevention : APJCP - 1 Jan 2014

Zhang Zhi-Rong, Duan Yan-Chao

Abstract excerpt

OBJECTIVE: To investigate interferon (IFN) alpha 2 b for treating patients with JAK2V617F positive polycythemia vera (PV) and essential thrombocytosis (ET). METHODS: Interferon alpha 2 b was used to treat patients with JAK2V617F positive PV and ET. In control group, hydroxyurea was used. Endpoint of study was to compare rates of hematological and molecular remission. RESULTS: Patients in the interferon alpha 2 b...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Hydroxyurea
Share to Interferon-alpha
Share to Interferon alpha-2

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Janus Kinase 2

Share to Polycythemia Vera

Share to Recombinant Proteins

Share to Thrombocythemia, Essential

Share to Thrombosis

Source

Identifiers

PMID: 24641389
DOI: 10.7314/apjcp.2014.15.4.1681

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interferon apha 2b for treating patients with JAK2V617F positive polycythemia vera and essential thrombocytosis.PMID 24641389Read ↗

Interferon α-2b gains high sustained response therapy for advanced essential thrombocythemia and polycythemia vera with JAK2V617F positive mutation.Semantic proximity Read ↗

Evidence and expertise in the management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

Pegylated interferon Alfa-2a and hydroxyurea in polycythemia vera and essential thrombocythemia: differential cellular and molecular responses.Semantic proximity Read ↗

[Interferon-alpha-2b induces molecular responses of patients with polycythemia vera and its post-polycythemic myelofibrosis].Semantic proximity Read ↗

How I treat polycythemia vera.Semantic proximity Read ↗

Contemporary Use of Interferon Therapy in the Myeloproliferative Neoplasms.Semantic proximity Read ↗

Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera.Semantic proximity Read ↗

Management of polycythemia vera and essential thrombocythemia.Semantic proximity Read ↗

The treatment of polycythaemia vera: an update in the JAK2 era.Semantic proximity Read ↗

Novel strategies for patients with chronic myeloproliferative disorders.Semantic proximity Read ↗

Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera.Semantic proximity Read ↗

Pegylated interferon: the who, why, and howSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.